SERD

News

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.

News

Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.

News

The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

News

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

News

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?